DE69812177T2 - 3'-epi k-252a derivate - Google Patents

3'-epi k-252a derivate Download PDF

Info

Publication number
DE69812177T2
DE69812177T2 DE69812177T DE69812177T DE69812177T2 DE 69812177 T2 DE69812177 T2 DE 69812177T2 DE 69812177 T DE69812177 T DE 69812177T DE 69812177 T DE69812177 T DE 69812177T DE 69812177 T2 DE69812177 T2 DE 69812177T2
Authority
DE
Germany
Prior art keywords
epi
derivatives
compounds
survival
enhancement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69812177T
Other languages
German (de)
English (en)
Other versions
DE69812177D1 (de
Inventor
L Hudkins
E Gingrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Cephalon LLC
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Cephalon LLC filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of DE69812177D1 publication Critical patent/DE69812177D1/de
Application granted granted Critical
Publication of DE69812177T2 publication Critical patent/DE69812177T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE69812177T 1997-12-31 1998-12-30 3'-epi k-252a derivate Expired - Lifetime DE69812177T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7026397P 1997-12-31 1997-12-31
PCT/US1998/027644 WO1999033836A1 (en) 1997-12-31 1998-12-30 3'-epimeric k-252a derivatives

Publications (2)

Publication Number Publication Date
DE69812177D1 DE69812177D1 (de) 2003-04-17
DE69812177T2 true DE69812177T2 (de) 2004-01-15

Family

ID=22094212

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69812177T Expired - Lifetime DE69812177T2 (de) 1997-12-31 1998-12-30 3'-epi k-252a derivate

Country Status (15)

Country Link
US (2) US6093713A (enExample)
EP (1) EP1044203B1 (enExample)
JP (1) JP4405667B2 (enExample)
KR (1) KR20010033737A (enExample)
CN (1) CN1285836A (enExample)
AT (1) ATE234308T1 (enExample)
AU (1) AU1947499A (enExample)
BR (1) BR9814543A (enExample)
CA (1) CA2315953C (enExample)
DE (1) DE69812177T2 (enExample)
DK (1) DK1044203T3 (enExample)
ES (1) ES2194385T3 (enExample)
NO (1) NO20003397L (enExample)
PT (1) PT1044203E (enExample)
WO (1) WO1999033836A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227371B2 (en) * 2000-12-08 2007-05-10 Ortho-Mcneil Pharmaceutical, Inc. Macroheterocylic compounds useful as kinase inhibitors
EP1721609A3 (en) * 2001-05-16 2007-01-31 GPC Biotech AG Pyridylpyrimidine derivatives as effective compounds against prion diseases
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
DE10161940A1 (de) 2001-12-17 2003-07-03 Nad Ag N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
US6723844B1 (en) * 2003-02-27 2004-04-20 Abbott Laboratories Preparation of K-252a
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
JP2010513287A (ja) * 2006-12-14 2010-04-30 トータティス， インク． 癌治療のための組成物及び方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62155284A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPH0826036B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
DE3752123T2 (de) * 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
DK0699204T3 (da) 1993-05-28 1999-02-22 Cephalon Inc Anvendelse af indolocarbazolderivater til behandling af en patologisk tilstand i prostata
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
DE69520554T2 (de) * 1994-07-04 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Verfahren zur herstellung von indolocarbazol-derivaten
WO1997005140A1 (en) 1995-07-31 1997-02-13 Novartis Ag Trindene compounds
WO1997007081A2 (en) 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis

Also Published As

Publication number Publication date
CA2315953A1 (en) 1999-07-08
WO1999033836A1 (en) 1999-07-08
EP1044203B1 (en) 2003-03-12
KR20010033737A (ko) 2001-04-25
ATE234308T1 (de) 2003-03-15
DE69812177D1 (de) 2003-04-17
AU1947499A (en) 1999-07-19
NO20003397L (no) 2000-08-31
US6451786B1 (en) 2002-09-17
DK1044203T3 (da) 2003-07-14
ES2194385T3 (es) 2003-11-16
BR9814543A (pt) 2000-10-10
EP1044203A1 (en) 2000-10-18
WO1999033836A9 (en) 2000-09-14
CN1285836A (zh) 2001-02-28
CA2315953C (en) 2010-11-09
JP2001527079A (ja) 2001-12-25
JP4405667B2 (ja) 2010-01-27
PT1044203E (pt) 2003-07-31
NO20003397D0 (no) 2000-06-29
US6093713A (en) 2000-07-25

Similar Documents

Publication Publication Date Title
CU23126A3 (es) Inhibicion de kinasa raf usando ureas heterociclicas sustituidas
TR200000151T2 (tr) Yeni bileşimler.
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
HN1998000143A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
NO962059L (no) Antiarytmiske benzodiazepiner
WO1999057117A3 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
ATE216871T1 (de) Derivate des pyrazolo-(1,5-a)-pyrimidine, dessen herstellung und haarfärbemittel mit solchen derivaten
FI971953A7 (fi) Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6 -aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit
MX9603479A (es) Derivados de 4-amino de acido micofenolico con actividad inmunosupresora.
ATE302606T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BR9608789A (pt) Compostos de tetralina com atividade de mdr
WO1992007830A3 (en) Oxindole peptide antagonists
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
ATE242234T1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
ATE222912T1 (de) Ausgewählte k-252a derivate
ATE234308T1 (de) 3'-epi k-252a derivate
DE69623819D1 (de) Furan- und thiophencarbothioamid derivate, deren herstellung und deren verwendung als inhibitoren der replikation von hiv-1 und hiv-1 mutanten
NO991734L (no) Pyrazolinoner for behandling av potensforstyrrelser
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
SU1786802A1 (ru) 2,4-ДИМЕТИЛ-9-ОКСИПИРИДО[1,2-a]ПИРИМИДИНИЙХЛОРИД, ОБЛАДАЮЩИЙ АНТИДЕПРЕССИВНОЙ АКТИВНОСТЬЮ
DE59809929D1 (de) 6-substituierte 1,2,4a,5a,8a,8b-hexahydro- und 1,2,3,4,4a,5a,8a,8b-oktahydro-6h-pyrrolo[3',4':4,5]furo[3,2-b]pyrid-8(7h)-on derivate und ihre verwendung zur bekämpfung von endoparasiten
MX9603483A (es) Acido micofenolico 6-sustituido y derivados.
ES2151820A1 (es) Herbicidas a base de derivados de 1,3-oxazin-4-ona, composiciones que los contienen y procedimiento para su preparacion.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition